Mustang Bio Says FDA Accepted Investigational New Drug Application For Blood Cancer Drug Candidate
10:29 AM EDT, 05/10/2021 (MT Newswires) -- Mustang Bio (MBIO) said Monday the US Food and Drug Administration has accepted its investigational new drug application to launch a phase 1/2 study of MB-106, which is intended for the treatment of relapsed or refractory CD20+ B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
The study will evaluate the safety, tolerability, and efficacy of the drug candidate.
The company collaborated with the Fred Hutchinson Cancer Research Center to develop the cell processing that will be used in the phase 1/2 trial, which is expected to begin enrollment in Q3, according to a statement.
Price: 2.97, Change: -0.08, Percent Change: -2.63